Ironwood Pharmaceuticals ...

0.88
0.00 (0.15%)
At close: Apr 25, 2025, 3:59 PM
0.89
1.59%
After-hours: Apr 25, 2025, 07:58 PM EDT

Ironwood Pharmaceuticals Revenue Breakdown

Period Ending Sep 30, 2024 Mar 31, 2024 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
Collaborative arrangement, collaboration and license agreements Revenue 413K 368K 121K 91K 151K 144K 148K 192K 114K 219K 200K 100K 300K 200K 200K
Collaborative arrangement, collaboration and license agreements Revenue Growth +12.23% +204.13% +32.97% -39.74% +4.86% -2.70% -22.92% +68.42% -47.95% +9.50% +100.00% -66.67% +50.00% 0.00% n/a
Royalty Revenue 700K 516K n/a 580K 570K 365K 409K 480K 396K 547K 408K n/a n/a n/a n/a
Royalty Revenue Growth +35.66% n/a n/a +1.75% +56.16% -10.76% -14.79% +21.21% -27.61% +34.07% n/a n/a n/a n/a n/a
Collaborative arrangement, other agreements Revenue 222K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Collaborative arrangement, other agreements Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Europe And Other Revenue 2.8M 2.4M 2.6M 2.3M 2.16M
Europe And Other Revenue Growth +16.67% -7.69% +13.09% +6.34% n/a
North America Revenue 433.24M 2.73M 2.71M n/a n/a
North America Revenue Growth +15763.86% +0.63% n/a n/a n/a

Operating Expense Breakdown

Period Ending Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 36.11M 36.96M 37.6M 37.57M 36.05M 52.48M 31.12M 28.39M 28.62M 30.12M 28.86M 28.69M 27.74M 27.05M 27.65M 33.98M 34.93M 34.64M 36.45M 39.19M 40.92M 43.25M 64.74M 58.18M 55.25M 68.36M 61.92M 57.95M 61.77M 57.79M 55.6M 55.21M 44.99M 36.92M 36.17M 31.51M 30.44M 32.95M 30.35M
Selling, General, and Administrative Revenue Growth -2.30% -1.70% +0.10% +4.22% -31.32% +68.67% +9.61% -0.80% -5.00% +4.38% +0.61% +3.41% +2.55% -2.17% -18.63% -2.71% +0.82% -4.96% -6.99% -4.23% -5.38% -33.20% +11.28% +5.31% -19.18% +10.40% +6.85% -6.19% +6.89% +3.93% +0.72% +22.72% +21.86% +2.07% +14.79% +3.51% -7.63% +8.60% n/a
Research and Development Revenue 29.83M 29.88M 25.3M 35.06M 32.98M 1.13B 12.85M 10.45M 11.54M 11.45M 10.82M 31.85M 10.91M 12.16M 15.48M 16.27M 21.69M 22.08M 28.03M 26.54M 27.55M 28.76M 53.99M 44.27M 46.79M 38.93M 36.51M 40.12M 37.06M 37.34M 33.7M 38.44M 37.53M 31.68M 31.84M 27.63M 25.83M 28.65M 26.64M
Research and Development Revenue Growth -0.18% +18.10% -27.84% +6.30% -97.07% +8657.11% +22.98% -9.52% +0.81% +5.82% -66.02% +192.02% -10.33% -21.45% -4.81% -25.01% -1.74% -21.23% +5.61% -3.68% -4.20% -46.73% +21.95% -5.39% +20.19% +6.65% -9.00% +8.23% -0.75% +10.81% -12.33% +2.44% +18.45% -0.50% +15.26% +6.96% -9.84% +7.53% n/a